GSK and Pfizer to combine consumer health businesses; British drugmaker plans to split into two businesses
GSK said the deal laid the foundation for the creation of two new UK-based global companies focused on pharmaceuticals/vaccines and consumer healthcare
GlaxoSmithKline Plc and Pfizer Inc said they would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), majority owned by the British company.
GSK said on Wednesday the deal laid the foundation for the creation of two new UK-based global companies focused on pharmaceuticals/vaccines and consumer healthcare.
For Pfizer, the deal resolves the issue of what to do with its consumer health division, which includes Advil painkillers and Centrum vitamins, after an abortive attempt to sell it outright earlier this year.
GlaxoSmithKline plans to split into two businesses — one for prescription drugs and vaccines, the other for over-the-counter products.
The revamp is the boldest move yet by Chief Executive Emma Walmsley, who took over last year.
She has previously played down the idea of breaking up the group, something that a number of investors have called for over the years.
The new joint venture with Pfizer is expected to generate total annual cost savings of 500 million pounds by 2022 for expected total cash costs of 900 million and non-cash charges of 300 million. GSK plans divestments of some 1 billion pounds.
In a bid to reassure investors of its financial strength, GSK extended its guarantee on the dividend by stating it expected to pay unchanged dividends of 80 pence per share for 2019.
Hindustan Unilever buys GSK's Indian Horlicks, Boost nutrition business in $3.8 billion all equity deal
The merger of GSKCH India with HUL will be on a basis of an exchange ratio of 4.39 HUL shares for each GSKCH India Share
GSK to sell Horlicks to fund $13 bn Novartis deal; Nestle, Kraft, Unilever likely suitors, say sources
GSK has started a strategic review of Horlicks - a malt-based drink brand popular in India – and some of its smaller products, after buying Novartis out of their consumer healthcare venture for $13 billion on Tuesday.
China has fined GlaxoSmithKline Plc a record 3 billion yuan ($488.8 million) for paying bribes to doctors to use its drugs, the British company said on Friday, drawing to a close a corruption probe that rocked the pharmaceutical sector in China.